Table 3.
Safety profiles during the first-line treatment in the S-1 maintenance group.
| Adverse events according to CTCAE V4.0 | With S-1 maintenance, n=74, count (%) | |
|---|---|---|
| All grades | Grade 3 or above | |
| Hematological adverse events | ||
| Leukopenia | 59 (79.7) | 22 (29.7) |
| Neutropenia | 61 (82.4) | 30 (40.5) |
| Thrombocytopenia | 28 (37.8) | 0 (0.0) |
| Anemia | 47 (63.5) | 6 (8.1) |
| Non-hematological adverse events | ||
| Hand-foot syndrome | 19 (25.7) | 1 (1.4) |
| Nausea and vomiting | 40 (54.1) | 1 (1.4) |
| Peripheral neurotoxicity | 49 (66.2) | 5 (6.8) |
| Elevated AST/ALT | 18 (24.3) | 0 (0.0) |
| Fatigue | 18 (24.3) | 1 (1.4) |
| Oral mucositis | 10 (13.5) | 1 (1.4) |
CTCAE V4.0, Common Terminology Criteria for Adverse Events, Version 4.0; AST, aspartate transaminase; ALT, alanine transaminase; NA, not assessable.